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Anticonvulsant Activity of Essential Oil From Leaves of 
Zhumeria majdae (Rech.) in Mice: The Role of GABAA 
Neurotransmission and the Nitric Oxide Pathway
Helia Aghamiri1,2, Hamed Shafaroodi3 and Jinous Asgarpanah4,*
The essential oil from the leaves of Zhumeria majdae Rech. (ZMEO) has been shown to have several beneficial effects in the 
clinic. In this work we examined the anticonvulsant activities of ZMEO in an experimental mouse model of seizure and aimed to 
identify any possible underlying mechanisms. ZMEO (5, 10, 20, and 40 mg/kg intraperitoneally (i.p.)) or diazepam, as the refer-
ence anticonvulsant drug (25, 50 and 100 µg/kg i.p.), were administered 60 minutes prior to pentylenetetrazol (PTZ) injection (in-
travenously (i.v.) or i.p.) and changes in threshold, latency, and frequency of clonic seizure were examined. The PTZ i.p.-induced 
model of seizure was also applied for examining the protective effects of ZMEO pretreatment against PTZ-induced mortality. 
In some studies, the anticonvulsant effect of the combination of diazepam and ZMEO was also studied. The protective effects 
of ZMEO against hindlimb tonic extensions (HLTEs) were also examined by maximal electroshock (MES) seizure testing. The 
γ-aminobutyric acid (GABA)ergic mechanism and nitric oxide (NO) pathway involvement in anticonvulsant activity of ZMEO were 
assessed by pretreating animals with flumazenil, Nω-nitro-L-arginine methyl ester (L-NAME), aminoguanidine, and L-arginine in 
a PTZ-induced model of seizure. Administration of 20 mg/kg ZMEO significantly increased chronic seizure threshold and latency 
while reducing frequency of convulsions and mortality in the PTZ-induced model. In the doses studied, ZMEO could not protect 
mice from HLTE and mortality induced by MES. Pretreatment with L-arginine and diazepam potentiated the anticonvulsant ef-
fects of ZMEO, whereas pretreatment with L-NAME, aminoguanidine, and flumazenil reversed anticonvulsant activity. The anti-
convulsant activity of ZMEO may be mediated in part through a GABAergic mechanism and the NO signaling pathway.
Affecting about 50–70 million people worldwide, epilepsy 
is responsible for 0.75% of the global burden of dis-
ease.1-3 The number of newly diagnosed cases of epilepsy 
worldwide is estimated to be around 2.4 million per year, 
with annual incidence of 50 in 100,000 and prevalence of 
700 in 100,000, making it one of the most frequent chronic 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  The essential oil derived from leaves of Zhumeria maj-
dae Rech. (ZMEO) has recently been shown to have sev-
eral beneficial effects in clinical practice. However, little 
is known about ZMEO’s potential anticonvulsant activity 
and its underlying pharmacologic mechanism of action.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Does ZMEO demonstrate significant anticonvulsant 
activity in experimental models of seizure? Is this anticon-
vulsant activity linked to the activation of γ-aminobutyric 
acid type A (GABAA) receptor or nitric oxide (NO)  
pathway?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  With linalool as its most abundant component, ZMEO 
demonstrated a meaningful anticonvulsant activity in 
both intravenous and intraperitoneal pentylenetetrazol-in-
duced mouse models of seizure. ZMEO, however, was not 
effective in the maximal electroshock model. These ef-
fects were partially mediated through activation of GABAA 
receptor and NO synthesis.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔  Our data present ZMEO as a novel antiepileptic agent, 
especially for application in the treatment of myoclonic/
generalized absence epilepsy, which is usually refractory 
to treatment. Furthermore, understanding the underlying 
mechanism of ZMEO’s anticonvulsant activity will help 
physicians in its rational application as a complementary 
component in combinational therapies to improve treat-
ment of resistant epilepsies.
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neurologic disorders.2 Approximately, 80% of epileptic 
patients reside in low- and middle-income countries (in-
cluding Asia, sub-Saharan Africa, and Latin America), 
where, due to poverty and/or unavailability of antiepileptic 
drugs (AEDs), three quarters of them lack proper therapy.2,4 
Unfortunately, the number of newly diagnosed cases of ep-
ilepsy in these low-income zones is about twofold higher 
than in high-income countries.2 In addition, about one 
third of epilepsy cases are nonresponsive or only partially 
responsive to currently existing AEDs. Similar numbers 
of patients also experience severe or unacceptable ad-
verse effects in response to AED therapy.5,6 Therefore, 
the challenge remains to identify new sources with greater 
affordability, higher clinical efficacy, and a safer toxicity 
profile. In recent few decades, much attention has been 
focused on plant extracts and essential oils as indigenous 
sources for development of new drugs. In this context, a 
diverse group of plant extracts and essential oils, includ-
ing extracts from Berberis vulgaris (L.), Passiflora incarnate 
(L.), and Pseudospondias microcarpa (A. Rich) Engl., have 
shown promising anticonvulsant effects in different models 
of seizure.7-9
There is a trend for identifying other new plant sources 
endemic in low- and middle-income countries for much eas-
ier accessibility and affordability. Zhumeria majdae Rech. 
(Labiatae) is an endemic fragrant shrub found in southern 
regions of Iran, especially the Hormozgan province, and typ-
ically grows on bare, rocky slopes. The folk name of this 
plant is “Mohrkhosh.” It is routinely utilized in Iranian tra-
ditional medicine as a carminative for infants and also for 
treatment of stomach aches, headaches, and dysmenorrhea 
in adults.10 Several recent reports have demonstrated an-
tiplasmodial,11 anti-inflammatory, and antioxidant activities 
of Z. majdae essential oil (ZMEO) and its extracts, both in 
vivo and in vitro.12-15 Now, it is clear that the antioxidant 
activity of Z.  majdae extract is largely due to its polyphe-
nolic components.12,15 Recently, Mandegary et al. reported 
the anticonvulsant activity of essential oil and methanolic 
extract of Z.  majdae in the maximal electroshock (MES) 
model of tonic seizure and showed that administration of 
Z. majdae could delay clonus and tonic seizures after intra-
peritoneal (i.p.) administration of pentylenetetrazol (PTZ).16 
Here, in parallel to a previous report, we attempted to further 
confirm the anticonvulsant activity of ZMEO and identify the 
probable underlying mechanisms, using different models of 
seizure.
MATERIALS AND METHODS
Collection of plant material and preparation of the 
essential oil
Fully matured leaves of Z. majdae were collected between 
March and April 2015 from the Genow-protected zone, 
located in Hormozgan province in southern of Iran. After 
identification and confirmation of leaves by Asadpour, 
a voucher code 1091-AUPF was sent to the herbarium 
at the School of Pharmacy, Tehran University of Medical 
Sciences, and the Islamic Azad University, Tehran, Iran. 
Hydrodistillation of the collected samples was then per-
formed in a Clevenger-type apparatus for 3 hours and the 
oil collected was dried (using anhydrous sodium sulfate) 
and then stored in a glass bottle at −18°C until further bio-
chemical analysis or application in pharmacologic tests.
Gas chromatography‒mass spectroscopic analysis of 
Z. majdae essential oil
Gas chromatography‒mass spectroscopy (GC-MS) was 
performed utilizing an HP-6890 gas chromatograph (GC) 
coupled with an HP-5973 Mass Selective Detector (MSD) 
(Agilent Technologies, Santa Clara, CA) functioning in 
70-eV mode. Identity of each component of essential oil 
was determined by comparing its mass spectra with those 
deposited in the mass spectral libraries, including Wiley 
NBS75K.L and NIST/EPA/NIH (2002 version; National 
Institute of Standards and Technology, Gaithersburg, MD), 
using different search engines.17,18
Animals
The study was carried out on adult male NMRI mice, 20–25 g 
in weight. The animals were housed with five or six animal 
per cage under regular 12-hour light/dark cycles and allowed 
to access food and water ad libitum, except for short peri-
ods when the pharmacologic tests were being carried out. 
Experiments were performed between 10.00 AM and 1:00 PM 
each day under regular room lighting and at ambient tempera-
ture. All animal experiments were complied with the ARRIVE 
guidelines  and carried out in accordance with the National 
Institutes of Health’s Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 8023, revised 1978). Mice were 
euthanized by cervical dislocation after completion of the 
tests. The whole study and the procedures included were ap-
proved by the ethics committee of the Tehran Islamic Azad 
University of Medical Sciences on August 1, 2013.
Experimental procedures
Intravenous PTZ-induced seizures model. Clonic seizure 
induced by PTZ is a standard experimental model of seizure, 
equivalent to clonic petit mal seizures in humans with both face 
and construct validity. The i.v. PTZ-induced model of seizure 
was used for studying the acute effect of ZMEO pretreatment 
on clonic seizure threshold (CST).19 Within the studied range 
of ZMEO pretreatment times (30, 60, and 120 minutes prior to 
PTZ administration), the best timepoint was the one with the 
largest increase in threshold of seizure, after administration 
of an effective concentration of ZMEO (20 mg/kg; Figure 1g). 
Based on the results, the best anticonvulsant activity was 
achieved when ZMEO was administered 60 minutes prior to 
PTZ infusion. Consequently, a 60-minute time interval was 
included between administration of ZMEO and infusion of 
PTZ in all experiments with measurement of clonic seizure 
threshold as their end point. Mice were classified into eight 
groups (eight mice per group) and treated with either ZMEO 
(5, 10, 20, or 40 ml/kg i.p.), diazepam (25, 50, or 100 µg/kg 
i.p.), or vehicle (sweet almond oil; 10 mg/kg i.p.) 60 minutes 
prior to i.v. infusion of PTZ (0.5% PTZ solution, 0.5 ml/min). 
Infusion was halted when full clonus of the body was seen. 
This usually occurs soon after initiation of forelimb clonus 
(Figure 1a).20 At this point, the total amount of PTZ delivered 
per kilogram of body weight in each mouse was calculated 




ZMEO Anticonvulsant Activity: Role of GABA and NO
Aghamiri et al.
Figure 1 A schematic representation of the study design. Animal models of seizure utilized in present study for investigating 
anticonvulsant activity of ZMEO, as well as the sequences of drug administration have been depicted in (a-f) and effect of pretreatment 
time on anticonvulsant activity of 20 mg/kg ZMEO has been demonstrated in (g). ZMEO, Zhumeria majdae (Rech.).
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For examination of possible enrollment of γ-aminobutyric 
acid type A (GABAA) receptors in protection induced by ZMEO 
in i.v. PTZ-induced model of seizure, flumazenil (0.5 mg/kg i.p.), 
a selective antagonist at the benzodiazepine binding site on 
the GABAA receptor, or vehicle was administered 15 minutes 
prior to injection of ZMEO (5 mg/kg i.p.) and diazepam (25 µg/
kg i.p.). In cases where effect of flumazenil on combination of 
diazepam and ZMEO was studied, diazepam and ZMEO were 
administered 5 and 15 minutes after injection of flumazenil, re-
spectively. After 60 minutes, mice were infused at a constant 
rate with PTZ (0.5 ml/min, 0.5%). Alterations in CST were re-
corded for each group separately and compared (Figure 1b).
The possible role of the nitric oxide (NO) pathway involve-
ment in the anticonvulsant activity of ZMEO was examined 
by pretreating mice with subeffective doses of L-arginine 
(30  mg/kg i.p.), a precursor for nitric oxide synthesis; Nω-
nitro-L-arginine methyl ester (L-NAME) (2.5  mg/kg i.p.), a 
nonselective inhibitor of nitric oxide synthase (NOS); and ami-
noguanidine (100 mg/kg i.p.), a selective inhibitor of inducible 
NOS (iNOS). This was done 15 minutes prior to administra-
tion of ZMEO (10 and 20 mg/kg i.p.). After 60 minutes, mice 
were infused with PTZ. Alterations in CST were then reported 
in response to pretreatment with modulators (Figure 1c). 
Doses of pharmacologic modulators were chosen according 
to pilot experiments and similar studies in the literature.21,22
Intraperitoneal PTZ-induced seizures. Short-term i.p. 
administration of PTZ (85  mg/kg) was done to evaluate 
the frequency and latency of generalized clonic seizure 
and incidence of death. Mice were classified into eight 
groups (eight mice per group) and received ZMEO (5, 10, 
20, or 40 ml/kg i.p.), diazepam (25, 50, or 100 µg/kg i.p.), 
or vehicle (sweet almond oil; 10  mg/kg i.p.) 60  minutes 
prior to IP infusion of PTZ, respectively (Figure 1d). The 
duration of monitoring after PTZ administration was 
limited to 30 minutes, and a latency of 1,800 seconds was 
recorded for experiments in which no generalized seizure 
occurred.23
For examination of possible enrollment of GABAA receptor 
in protection induced by ZMEO in the i.p. PTZ-induced seizure 
model, flumazenil (0.5  mg/kg) or vehicle was administered 
15 minutes before injection of ZMEO (20 mg/kg) and diaze-
pam (25 µg/kg). In cases where the effect of flumazenil on the 
combination of diazepam and ZMEO was studied, diazepam 
and ZMEO were administered 5 and 15 minutes after injec-
tion of flumazenil, respectively. After 60 minutes, mice were 
intraperitoneally injected with PTZ (85 mg/kg). Alterations in 
latency and frequency of clonic convulsions were then re-
corded for each group separately and compared (Figure 1e).
Maximal electroshock seizure test. The seizures were 
induced by MES in male NMRI mice with the help of an 
electroconvulsiometer by passing current of 35 mA at 50 Hz 
for 0.2 second using ear clip electrodes. Mice were classified 
into five groups, each consisting of 10 mice. ZMEO (5, 20, 
and 40  mg/kg), phenytoin (25  mg/kg), or vehicle (sweet 
almond oil; 10 mg/kg i.p.) were given 1 hour prior to seizure 
induction. Drops of saline were instilled in both ears to 
ensure current transmission. The ability to reduce mortality 
and incidence rate of tonic hindlimb extension (THLE) were 
used as end points for evaluating the protective effects of 
ZMEO against the MES-induced seizure model.24,25
Statistical analysis
Throughout the experiments, sample sizes of eight to ten 
were used. Clonic seizure frequency, latency, and thresh-
old obtained from the i.p. and i.v. PTZ-induced models of 
seizure are expressed as mean ± SEM. One-way analysis 
of variance (ANOVA) with Newman-Keuls post hoc test 
was used for comparing clonic seizure thresholds and 
frequencies between groups. The Kruskal-Wallis nonpara-
metric test was used to compare clonic seizure latencies 
among groups, as data did not demonstrate a normal dis-
tribution. Two-way ANOVA with Bonferroni’s post hoc test 
was applied for analyzing experiments in which the pos-
sible roles of the GABAergic system and NO pathway in 
anticonvulsant activity of ZMEO were studied. In the i.p. 
model of PTZ-induced seizure, the Kaplan-Meier test was 
applied for evaluating survival relative to time. Differences 
in survival were then analyzed using the log-rank test. 
Statistical analysis was performed using GraphPad Prism 
version 8.0 (GraphPad Software, San Diego, CA). P < 0.05 
was considered statistically significant for all experiments.
RESULTS
Chemical composition of ZMEO
The yield of ZMEO extraction based on native plant ma-
terial was 9.3%. The main terpenoids identified in ZMEO 
were linalool (61.4%) followed by camphor (27.5%). Other 
major components found include cis-linaloloxide (1.11%), 
limonene (0.98%), and geraniol (0.9%) As shown in Figure 2 
and Table 1, 16 major compounds formed ~ 98.8% of the 
total essential oil. With regard to the predominance of lin-
alool and camphor in the formulation, the biologic effects 
observed may in large part be attributed to the pharmaco-
logic activity of these two terpenes.
Effect of ZMEO on i.p. and i.v. PTZ-induced seizure 
models
Administration of ZMEO in the i.v. PTZ-induced seizure model 
resulted in a dose-dependent increase in clonic seizure 
threshold, with statistical significance beginning at 10  mg/
kg (P < 0.05), suggesting protective effects of ZMEO against 
petit mal clonic seizure (F(3, 28) = 79.87, P < 0.0001; Figure 3b). 
Notably, 40 mg/kg ZMEO demonstrated a submaximal effect 
compared with 20 mg/kg ZMEO. In addition, one-way ANOVA 
demonstrated that ZMEO could significantly reduce frequency 
of clonic convulsions at all doses examined (P < 0.0001) in the 
i.p. PTZ-induced seizure model (F(3, 36) = 40.28, P < 0.0001; 
Figure 3a). Kruskal-Wallis analysis consistently revealed a 
statistically significant increase in latency of clonic convul-
sions only at 20 mg/kg ZMEO in the i.p. PTZ-induced seizure 
model (P < 0.05; Figure 3a). Diazepam as the reference anti-
convulsant agent increased the clonic seizure threshold, with 
PTZ (mg/kg)=




ZMEO Anticonvulsant Activity: Role of GABA and NO
Aghamiri et al.
statistical significance beginning at 50 µg/kg in the i.v. PTZ-
induced seizure model (F(3, 28) = 19.34, P < 0.0001; Figure 3d). 
Also, pretreatment with diazepam meaningfully delayed onset 
of clonic convulsions (P  <  0.001 for 50 and 100  µg/kg; 
Figure 3c) and reduced the frequency of clonic convulsions 
(F(3, 36) = 116.1, P < 0.0001; Figure 3c) at all concentrations in 
the i.p. PTZ-induced seizure model.
As shown in Figure 4a, administration of ZMEO dose-de-
pendently (with statistical significance beginning at 20 mg/
kg; P = 0.002, χ2(df = 3) = 14.71) improved animal survival 
after induction of convulsions by i.p. administration of PTZ. 
When compared with the vehicle group, mortality in mice 
pretreated with diazepam (25  mg/kg i.p.) was not signifi-
cantly different from that in the control group (P  =  0.079, 
χ2(df  =  1)  =  3.08). In contrast, concurrent administration 
of 5  mg/kg ZMEO with 25  µg/kg diazepam prevented 
death by i.p. administration of PTZ in all mice (P = 0.0003, 
χ2(df = 1) = 13.39; Figure 5b).
Effect of ZMEO on maximal electroshock-induced 
seizure model
Administration of electrical shock produced THLEs in al-
most all mice in the vehicle group (Table 2). Administration 
of ZMEO at the doses studied also did not produce any pro-
tective effects against THLEs. In contrast, administration 
of 25 mg/kg phenytoin completely protected mice against 
THLE and MES-induced death.
GABAA receptor is partially involved in protective 
anticonvulsive effects of ZMEO
As depicted in Figure 5a,b, administration of 20 mg/kg 
ZMEO or 25  µg/kg diazepam significantly increased la-
tency while decreasing frequency of clonic convulsions 
in the i.p. PTZ-induced seizure model. Furthermore, a 
synergistic increase in latency and a decrease in num-
ber of clonic convulsions were observed when ZMEO 
and diazepam were administered together in the model. 
Interestingly, pretreatment with flumazenil (0.5  mg/kg 
i.p.), which when given alone did not demonstrate any 
significant effect on latency or frequency of clonic con-
vulsions, completely reversed the anticonvulsant effects 
of ZMEO, diazepam, and their combination by decreas-
ing latency and increasing frequency of clonic seizures 
in the i.p. PTZ-induced seizure model up to levels 
observed in vehicle-administered mice (frequency: 
F(1, 56)  =  74.42,  P  <  0.0001; latency: F(1,56)  =  1,356, 
Figure 2 Experimental chromatogram of ZMEO obtained by GC-MS. The mass analysis of Linalool and Camphor has also been 
provided in scheme. ZMEO, Zhumeria majdae (Rech.).
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Table 1 The 16 most abundant components of ZMEO in order of their retention time and their abundancy and structure
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P  <  0.0001). As shown in Figure 5c, administration of 
ZMEO (5 mg/kg i.p.) and diazepam (25 µg/kg i.p.) did not 
significantly increase threshold of clonic convulsions in 
the i.v. PTZ-induced seizure model. However, concurrent 
administration of the two therapies resulted in a significant 
increase in threshold of clonic seizure. This finding sug-
gests a synergistic effect for concurrent administration of 
these agents, which may occur through a common path-
way in the i.v. PTZ-induced seizure model. Interestingly, 
pretreatment with flumazenil (0.5 mg/kg i.p.), which on its 
own did not demonstrate any significant effect on thresh-
old, completely reversed the anticonvulsant effect of a 
combination up to the levels observed in vehicle-admin-
istered mice (F(1, 28) = 30.82, P < 0.0001). Furthermore, the 
protective effects of ZMEO and combination of ZMEO and 
diazepam against PTZ-induced mortality was completely 
reversed by pretreating mice with flumazenil (Figure 4b). 
These results strongly suggest that GABAA receptors are 
at least partially involved in the anticonvulsant activity ob-
served with ZMEO.
NO pathway is partially involved in protective 
anticonvulsive effects of ZMEO
The lower row in Figure 5 demonstrates the modulatory ef-
fects of L-arginine, L-NAME, and aminoguanidine effects on 
the anticonvulsant activity of ZMEO in the i.v. PTZ-induced 
seizure model. Short-term treatment with ZMEO (10 and 
20  mg/kg i.p.) significantly increased threshold of clonic 
convulsions. L-Arginine (30  mg/kg i.p.) pretreatment did 
not have any significant effect on threshold of convulsions 
compared with vehicle-administered mice. However, pre-
treatment with L-arginine significantly increased ZMEO’s 
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protective effects by increasing the threshold of clonic sei-
zures (F(1, 42) = 21.66, P < 0.0001; Figure 5d). Pretreatment 
of mice with either L-NAME (2.5 mg/kg i.p.) or aminoguan-
idine (100 mg/kg i.p.) significantly reduced anticonvulsant 
activities of ZMEO, as is evident from a decline in threshold 
of clonic convulsions in the i.v. PTZ-induced seizure model 
(L-NAME (F(1, 42)  =  134.6, P  <  0.0001); aminoguanidine 
(F1,24 = 115, P < 0.0001); Figure 5e,f).
DISCUSSION
Based on results obtained from GC-MS analysis, linalool 
and camphor were the main components of ZMEO. Linalool 
is a tertiary alcohol belonging to acyclic monoterpenoid, 
which is also a common floral scent found in nature. Several 
studies have reported on the potential inhibitory effect of 
linalool on neural excitability in a variety of experimental 
mouse models of seizure. For instance, administration of 
linalool was found to delay onset of seizure in the NMDA 
model or protect against picrotoxin, quinolinic acid, pen-
tylenetetrazol, and transcorneal electroshock-induced 
models of seizure.26 Proposed pharmacologic mechanisms 
for these anticonvulsant effects include dose-dependent 
antagonism of glutamate NMDA receptors, agonistic effect 
on GABAA receptors and inhibition of intracellular accu-
mulation of cyclic adenosine monophosphate (cAMP),27 
modulation of nicotinic receptor‒ion channel kinetics, 
alteration in calcium channel blocking, and an inhibitory ef-
fect on acetylcholine secretion.28 Based on findings by De 
Sousa et al.,25 single enantiomers of linalool demonstrate 
different potencies when compared with their racemic for-
mulations. It has been shown that the (S)/(+) enantiomer is 
less effective compared with the (R)/(−) enantiomer and ra-
cemic formulation. The anticonvulsant activity of two latter 
forms of linalool has been shown to be comparable with 
activities seen with diazepam and phenytoin.29
The capability of different components of ZMEO in 
opening the GABAA receptor has been demonstrated 
in several reports utilizing the patch-clamp technique. 
Based on work by Kessler et al., compared with GABA 
application alone, application of linalool (forming 63.4% 
of ZMEO) can increase mean current amplitude by two-
fold.30,31 In addition, although camphor (forming 27.4% of 
ZMEO) can mildly potentiate GABAA receptor‒mediated 
currents, borneol (forming 0.9% of ZMEO) can effectively 
enhance it in patch-clamp studies.32 As about 93% of 
Figure 3 Anticonvulsant activity of ZMEO (5–40 mg/kg) and diazepam (25–100 µg/kg) on (a,c) frequency, (a,c) latency of convulsions 
in i.p. PTZ-induced seizure model, and (b,d) threshold of convulsions in i.v. PTZ-induced seizure model. Data represent mean ± SEM 
and each group comprised of eight mice. *P < 0.05, **P < 0.01, and ***P < 0.001 vs vehicle group (control). Analyses were performed 
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ZMEO’s components are capable of potentiating GABAA 
receptor current in patch-clamp‒based studies, it can 
be reliably predicted that overall EO formulation can also 
modulate GABAA receptors. Other components with a 
lower ZMEO formulation, including α-pinene, geranial, ge-
raniol, caryophyllene, and limonene, are also capable of 
enhancing GABAA receptor current.
31 In parallel, in exper-
iments other than epilepsy, modulatory effects of ZMEO 
components on voltage-dependent Na+  channels have 
also been observed. For instance, the antinociceptive ef-
fect of linalool was shown to originate from a decrease in 
voltage-dependent Na+ current in neurons located in the 
dorsal root ganglia, or terpinen-4-ol, which was shown to 
be capable of decreasing Na+ current in electrophysiology 
studies.33
Currently, MES- and PTZ-induced models of seizure are the 
most widely utilized tests for preclinical examination of anti-
convulsant activity in new investigational AEDs. In this context, 
MES is capable of identifying compounds with preventive ef-
fects against spread of seizure, whereas PTZ mostly identifies 
agents with the capacity to increase seizure threshold.34,35
With a few exceptions, an appropriately designed i.p. 
PTZ-induced seizure model was shown to be consistent 
for assessment of human myoclonic jerks and spike-wave 
seizures. With this test, the suppressive effects of an inves-
tigational AED on clonic seizure induced by a proconvulsive 
i.p. dose of PTZ can be monitored. Thus, the i.p. PTZ-
induced model of seizure is capable of only evaluating the 
ability of a compound to block a specific end point in quan-
tal mode. That is, it can only inform us as to whether or not 
Figure 4 Kaplan-Meier analysis for estimation of overall survival of animals receiving (a) ZMEO (5, 20, and 40 mg/kg) and (b) diazepam 
(25 µg/kg), diazepam + ZMEO, and flumazenil (0.5 mg/kg) pretreated diazepam + ZMEO, in a i.p. PTZ-induced seizure model over a 
30-minute observation period (n = 10). ZMEO, Zhumeria majdae (Rech.).
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a specific compound can prevent a seizure end point.36,37 
Although measurement of alterations in parameters, in-
cluding latency to onset, severity, and duration of clonus 
seizure response, have been applied recently for quantifying 
responses in the i.p. model, high inter-animal variability in 
latency of seizure onset resulted in a significant decrease 
in precision of the results.38 Finally, evaluation of an investi-
gational AED’s ability to improve survival may be effectively 
evaluated with this test.39
In contrast, the i.v. PTZ-induced model of seizure is 
widely applied to provide data other than those provided 
by the i.p. PTZ-induced seizure model. The i.v. model of-
fers a highly sensitive parametric approach for measuring 
seizure threshold.40 That is, instead of only identifying an 
agent with a comprehensive preventive effect on seizure 
occurrence, all agents capable of delaying its appearance 
can be identified. Thus, a quantifiable end point can be 
achieved by performing this test. Regarding the diversity 
of end points associated with each model, in the pres-
ent study both i.p. and i.v. PTZ-induced models of seizure 
were used for acquiring a comprehensive data set for an-
ticonvulsant activity of ZMEO. The i.p. model was applied 
mainly for evaluating improvements in survival rate, la-
tency to onset, and severity and duration of clonus seizure 
response in ZMEO-pretreated mice and i.v. PTZ-induced 
mice for measuring seizure susceptibility in each individual 
animal.
Like other EOs, absorbed ZMEO in blood after IP ad-
ministration will freely pass through the blood-brain barrier 
(BBB) to reach its site of action in the central nervous sys-
tem (CNS). This happens mainly owing to its very small size 
(< 400 Da) and high lipid solubility in all components found 
in EOs.41,42 The dose-response curve obtained in the i.v. 
PTZ-induced seizure model in the present study did not dis-
play the classic sigmoidal dose-response pattern. Instead, 
as depicted in Figure 3a,b, ZMEO treatment produced a 
Figure 5 Effects of flumazenil pretreatment on (a) latency and (b) frequency of ZMEO (5 or 20 mg/kg) and diazepam (25 µg/kg) receiving 
mice in i.p. PTZ-induced seizure model, and (c) threshold of ZMEO (5 or 20 mg/kg), diazepam (25 µg/kg), and ZMEO + diazepam (5 mg/
kg and 25 µg/kg) receiving mice in i.v. PTZ-induced seizure model. Each group consisted of eight mice and data are presented as 
mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 vs vehicle group (control) (one-way ANOVA and Newman-Keuls post hoc testin 
used for frequency and threshold, and Kruskal-Wallis nonparametric test used for latency). #P < 0.05, ##P < 0.01, and ###P < 0.001 
vs flumazenil-treated group (two-way ANOVA followed by Bonferroni’s test). (d) Effects of pretreating mice with L-Arginine (30 mg/
kg), (e) L-NAME (2.5 mg/kg), and (f) aminoguanidine (100 mg/kg) on the threshold of ZMEO (10 and 20 mg/kg) in i.v. PTZ-induced 
seizure model. L-Arginine, L-NAME, aminoguanidine, or vehicle (control) were administered 15 minutes before injection of ZMEO and 
75 minutes before induction of seizure by i.v. infusion of PTZ. Each group consisted of eight mice and data represent mean ± SEM. 
*P < 0.05, **P < 0.01, and ***P < 0.001 vs vehicle group (control) (one-way ANOVA and Newman-Keuls post hoc testing). Significance 
of differences between groups were analyzed using two-way ANOVA and Bonferroni’s post hoc test: #P < 0.05, ##P < 0.01, and 
###P  <  0.001. ANOVA, analysis of variance; i.p., intraperitoneal; i.v., intravenous; L-NAME, Nω-nitro-L-arginine methyl ester; PTZ, 
pentylenetetrazol; ZMEO, Zhumeria majdae (Rech.).
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biphasic dose-response curve, raising the seizure thresh-
old up to a maximum of about twofold that of control at its 
maximum effective dose (20 mg/kg), while beginning to pro-
gressively lose its anticonvulsant activity and demonstrate 
reduced anticonvulsant activity as the dose increased from 
20 to 40  mg/kg. A similar pattern was also observed for 
latency of seizure onset upon administration of increasing 
doses of ZMEO. Similarly, studies have shown that primi-
done, phenytoin, and carbamazepine also had U-shaped, 
nonlinear responses in PTZ seizure‒induced models. Similar 
to ZMEO, anticonvulsant effects were reported at relatively 
low doses, while the effects were significantly decreased or 
completely vanished at higher doses.38 This pattern of re-
sponse, at least for phenytoin and carbamazepine, has been 
ascribed to their proconvulsive behavior at high concentra-
tions, both in rodents and humans.43-45
Indeed, the proconvulsive activity observed with carba-
mazepine, phenytoin, and herein ZMEO may be attributed 
to the hyperexcitability of neuronal networks mediated by 
intensive activation of GABAA receptors at high doses of 
these agents. It has been shown that an intensive short-term 
GABAA receptor activation can switch primary hyperpo-
larizing responses (i.e., anticonvulsant effects) of GABA 
to depolarizing or excitatory responses in normal brain. 
During an intensive activation of GABAA receptor (herein 
administration of high doses of ZMEO), even in the absence 
of structure-based change of the chloride transporters, in-
creased Cl− influx will overcome its extrusion and result in 
accumulation of chloride and an increase in [Cl−]i, which in 
turn can induce a depolarizing shift in reversal potential of 
the GABAA receptor in postsynaptic cells. However, as the 
affinity and subtypes of GABAA receptors are regionally dif-
ferent in the CNS, similar doses of ZMEO may demonstrate 
protective effects in some sections. Thus, the overall effect 
may be only a reduction in ZMEO protective effects but not 
a complete reversal of the effect.46
In addition, in a very similar study, evaluating the effects 
of opioids on seizure threshold, Lauretti et al. demonstrated 
that morphine, fentanyl, and pethidine are capable of 
demonstrating such biphasic responses in four models of 
seizure, namely PTZ, kainic acid, N-methyl-D,L-aspartate 
(NMDLA), and bicuculline. Regardless of the individual pat-
tern of each opiate in the different models studied (whether 
anti- or proconvulsive responses), coadministration of nal-
oxone could reverse the opiate effect in the low dose range, 
strongly suggestive of the enrollment of µ-opioid receptors 
in the observed effects. In contrast, coadministration of 
naloxone in the high dose range demonstrated complex 
responses, with pethidine being completely insensitive in 
all studied models and fentanyl and morphine in the bicu-
culline-induced seizure model. The main outcome of this 
study on mechanistic insight into these biphasic responses 
is that other non-opiate receptors may also be involved.47 
Accordingly, Homayoun et al. demonstrated that anti-
convulsive effects of morphine could be suppressed with 
administration of clonidine, an α2-adrenoceptor agonist, or 
potentiated by yohimbine, an antagonist for this receptor.48 
In the case of ZMEO, consisting of 16 components, explor-
ing the mechanism of this biphasic response may become 
somehow more complex. However, as stated earlier, one 
possible mechanism may be the activation or involvement 
of receptors other than GABAA.
Flumazenil is a selective antagonist for the benzodiaz-
epine site on GABAA  receptors, which is mainly applied 
in the clinic for reversing benzodiazepine overdose.49-51 
Flumazenil has been widely applied as a powerful tool 
for exploring benzodiazepine/GABAA  receptor interaction 
in animals and humans, with the purpose of searching 
endogenous or exogenous ligands for this receptor.52 
Based on our results, involvement of GABAA receptor was 
confirmed in three ways: (1) As depicted in Figure 5c, 
coadministration of diazepam and ZMEO, both in subef-
fective concentrations, induced protective effects in the 
PTZ model. Therefore, two components must have had an 
additive or synergistic effect together, which could have 
antagonized the proconvulsive effects of PTZ. Because, 
at the molecular level, a generally accepted mechanism of 
PTZ is noncompetitive antagonism of the GABAA receptor 
complex, a combination of the two drugs must have re-
versed the antagonizing effect of PTZ on GABAA receptor. 
As diazepam efficacy in this context was not high enough 
at the concentrations administered, the extra stimulatory 
effect on GABAA receptor must have been compensated 
by ZMEO.53 Furthermore, because ZMEO at high doses 
could increase the threshold of PTZ-induced seizure, it 
must have at least partially reversed the antagonizing ac-
tivity of PTZ on GABAA. (2) Administration of flumazenil 
completely antagonized both components effects. As the 
only known mechanism of flumazenil is ligation to GABAA 
receptor, ZMEO must have modulated the GABAA receptor 
activity. (3) Similar protective effects can also be observed 
by survival analysis, as shown in Figure 4.
Synthesized from its precursor L-arginine through the 
action of NOS enzyme, NO is a gaseous free radical that 
functions as a neurotransmitter-modulating agent and 
neural messenger in the CNS.54 NO is considered an en-
dogenously expressed anticonvulsant agent, because 
inhibition of its synthesis through administration of NOS 
inhibitors has been shown to occur together with exacer-
bation of seizures in experimentally induced rat models of 
seizure.55,56 Consistently, administration of L-arginine at 
concentrations high enough to increase NO levels could re-
verse proconvulsive effects of NOS inhibitors. In addition, 
administration of L-arginine could prevent rodents against 
sound and picrotoxin proconvulsive effects.57,58 Marangoz 
Table 2 Protective effects of ZMEO and phenytoin on MES-induced 









Control   100 33.3
ZMEO (mg/kg) 5 100 33.3
20 100 50
40 100 33.3
Phenytoin (mg/kg) 25 0 0
Data represent the percentage of mice (n  =  10) producing THLE and 
mortality.
MES, maximal electroshock; ZMEO, Zhumeria majdae Rech.
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et al.59 demonstrated that administration of a NO donor, so-
dium nitroprusside, could reverse epileptiform discharges 
induced by intracortical administration of penicillin in rats. 
Administration of L-arginine at concentrations high enough 
to increase NO levels has been shown to indirectly in-
crease GABA levels through inhibiting the function of GABA 
transaminase (GABA-T), a specific enzyme involved in me-
tabolization of GABA.60-62 In addition, NO is capable of 
increasing the secretion of GABA from different regions of 
brain, including cortex, striatum, and hippocampus.63-65 In 
addition, increased NO and GABA levels through the action 
of L-arginine could protect rats from picrotoxin-induced 
seizure.58 Thus, L-arginine could promote both secretion 
and synthesis of GABA in the CNS as a function of in-
creased secretion of NO. Consistent with this finding, Paul 
et al. demonstrated an additive function for L-arginine upon 
coadministration with phenobarbital, a well-known GABA-
potentiating agent.66
Based on the data obtained, it can be hypothesized that 
ZMEO pretreatment enhanced production of NO, and this 
upregulation in CNS levels of NO was enough to protect 
against the proconvulsive effects of gradually increasing 
concentrations of PTZ. This happens because synthesized 
NO increases GABA concentration through enhancing its 
secretion from different compartments of the CNS and de-
creasing its metabolism by inhibiting GABA-T. In view of 
this unique form of administration (i.v. infusion), the initial 
concentration of PTZ in the mouse body is very low and in-
creases at a slow rate. Therefore, the amount of PTZ will not 
be high enough to promote secretion of an adequate volume 
of glutamate required for activating NMDARs and inducing 
production of proconvulsive concentrations of NO. Instead, 
an enhanced level of GABA at the site of action (GABAA re-
ceptor) compensates for the noncompetitive antagonizing 
effect of PTZ. This hypothesis is much strengthened consid-
ering the fact that administration of L-arginine, a precursor 
of NO, at concentrations not sufficient to significantly affect 
clonic seizure threshold, could significantly enhance the 
anticonvulsant effects of ZMEO at both submaximal and 
maximal concentrations. Furthermore, pretreating mice with 
both of the NOS inhibitors, as done in the present study 
with L-NAME and aminoguanidine, with concentrations not 
enough to significantly affect clonic seizure threshold, could 
completely reverse the anticonvulsant effects seen with ad-
ministration of ZMEO.
In conclusion, based on the data obtained in the present 
study, the essential oil obtained from leaves of Z. majdae 
could demonstrate a biphasic anticonvulsant response in 
both i.v. and i.p. PTZ-induced seizure models and could 
effectively increase survival rate in i.p. PTZ-administered 
mice. ZMEO, however, was not effective in the maximal 
electroshock-induced model of seizure, but showed poten-
tial for antiepileptic activity against myoclonic/generalized 
absence epilepsy. This is very important as absent seizure 
is mostly refractory to currently existing antiepileptic drugs, 
with development or discovery of new lead compounds 
with much higher potency and efficacy being of utmost 
importance. Applying different pharmacologic agonists 
and antagonists of GABAA receptor, precursors of NO, and 
different inhibitors of NOS revealed that anticonvulsant 
activity of ZMEO is mediated in part through activation of 
the GABAA pathway and NO synthesis. Finally, understand-
ing the underlying mechanism of ZMEO’s anticonvulsant 
activity will help physicians in its rational application as a 
complementary component in combinational therapies for 
resistant epilepsies.
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